Analyst Price Targets — ADAG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 14, 2026 10:44 am | Paul Jeng | Guggenheim | $10.00 | $3.82 | StreetInsider | Guggenheim Reiterates Buy Rating on Adagene Inc (ADAG) |
| September 19, 2024 6:48 am | Arthur He | H.C. Wainwright | $5.00 | $2.15 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Adagene Inc (ADAG) |
| April 8, 2024 4:23 pm | Matthew Harrison | Morgan Stanley | $5.00 | $2.83 | StreetInsider | Adagene Inc (ADAG) PT Raised to $5 at Morgan Stanley |
Latest News for ADAG
SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York. 2026 Cantor Global Healthcare Conference; New York, NY –…
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ADAG.
U.S. House Trading
No House trades found for ADAG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.